Ertl Hildegund C J
Wistar Institute, 3600 Spruce Street, Philadelphia, PA 19104, USA.
Curr Opin Mol Ther. 2002 Dec;4(6):601-5.
Therion Biologics, in collaboration with Aventis Pasteur, is developing ALVAC-CEA/B7.1, a recombinant, pox virus-based vaccine that targets carcinoembryonic antigen (CEA) found on the surface of lung and colorectal tumor cells, for the potential treatment of lung and colorectal cancer. The vaccine is in phase II clinical trials for these indications.
赛立昂生物公司（Therion Biologics）与安万特巴斯德公司（Aventis Pasteur）合作，正在研发ALVAC-CEA/B7.1，这是一种基于痘病毒的重组疫苗，靶向在肺癌和结直肠肿瘤细胞表面发现的癌胚抗原（CEA），用于肺癌和结直肠癌的潜在治疗。该疫苗针对这些适应症正处于II期临床试验阶段。
